4.8 Article

Two-dimensional porous vermiculite-based nanocatalysts for synergetic catalytic therapy

Journal

BIOMATERIALS
Volume 295, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2023.122031

Keywords

Two-dimensional nanomaterials; Sonodynamic therapy; Chemodynamic therapy; Gas therapy; Vermiculite

Ask authors/readers for more resources

This study presents a nanocatalyst platform (Arg@VMT@PDA-PEG) based on ultrasound-mediated and two-dimensional porous vermiculite nanosheets (VMT NSs), which synergistically harnesses Fenton reaction-based chemodynamic therapy (CDT), 2D semiconductor-based sonodynamic therapy (SDT), and nitric oxide (NO)-based gas therapy for combination cancer therapy.
This study reports an ultrasound-mediated and two-dimensional (2D) porous vermiculite nanosheets (VMT NSs)-based nanocatalyst platform (Arg@VMT@PDA-PEG) that synergistically harnessed the Fenton reaction-based chemodynamic therapy (CDT), 2D semiconductor-based sonodynamic therapy (SDT) and nitric oxide (NO) -based gas therapy for combination cancer therapy. The tumor microenvironment responsive degradation of polydopamine (PDA) shell could not only prevent L-Arg, a NO donor, leakage during blood circulation, but also selectively release the active sites of VMT NSs for catalytic reactions in tumor cells. Additionally, the Fenton reactions mediated by the abundant Fe2+/Fe3+ in VMT NSs could efficiently produce center dot OH and consume gluta-thione (GSH) for CDT. Moreover, the reactive oxygen species (ROS, center dot OH and center dot O-2(-)) produced by ultrasound-triggered Arg@VMT@PDA-PEG could not only execute SDT but also oxidize L-Arg to NO for synergetic gas therapy. The results show that the transformation of ROS to NO can enhance curative efficacy owing to the ability of NO with much longer life-time in freely diffusing into cells from intercellular space. This biodegradable Arg@VMT@PDA-PEG nanocatalytic platform integrating three different catalytic reactions provides a new therapeutic paradigm for combination cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available